Data demonstrate compelling evidence of the immune-stimulatory properties linked to TLR-3 activation through Ampligen Data demonstrate compelling evidence of the immune-stimulatory properties linked to TLR-3 activation through Ampligen

View original post here:
AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal...

AUSTIN, Texas, March 25, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today announced the completion of another interim safety review of simufilam in on-going Phase 3 clinical trials in patients with Alzheimer’s disease. A routine, scheduled meeting of a Data and Safety Monitoring Board (DSMB) recommended that both of Cassava Sciences’ on-going Phase 3 studies continue as planned, without modification.

Go here to see the original:
Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials

THE WOODLANDS, Texas, March 25, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that four data presentations related to sotagliflozin, an inhibitor of two sodium glucose transport proteins (SGLT2 and SGLT1), will be delivered during the American College of Cardiology 73rd Annual Scientific Session & Expo being held April 6 - 8, 2024 in Atlanta, Georgia, including results from a post-hoc evaluation of the efficacy of sotagliflozin in reducing stroke events in patients with type 2 diabetes, chronic kidney disease (CKD), and high cardiovascular (CV) risk in the SCORED Phase 3 clinical trial.

See the original post here:
Clinical Data on the Impact of Sotagliflozin on Stroke and Heart Attack Risk Among Four Lexicon-Sponsored Presentations at the American College of...

Specialty Pharmaceutical Company Deploys TransPerfect Technology to Streamline TMF Operations Specialty Pharmaceutical Company Deploys TransPerfect Technology to Streamline TMF Operations

See the article here:
Gedeon Richter Selects Trial Interactive for Clinical Trial Management

Revisionen af selskabets årsrapport for 2023 er ikke afsluttet. Årsrapporten offentliggøres på onsdag den 27. marts 2024 i henhold til selskabets finanskalender.

Read this article:
Foreløbige tal for 2023 og finansielle forventninger til 2024

OXURION announces its presence at the Paris SmallCapevent on March 28, 2024.

More here:
OXURION announces its presence at the Paris SmallCap event on March 28, 2024.

Topline data from the randomized Phase 2b KICKSTART trial of tomivosertib combined with pembrolizumab in non-small cell lung cancer (NSCLC) expected in early April 2024

Read the original:
eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

RESEARCH TRIANGLE PARK, N.C., March 25, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference on Thursday, March 28, 2024, at 2:30 p.m. ET and the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024, at 10:15 a.m. ET.

Read more:
BioCryst to Present at Upcoming Investor Conferences

Presentation will be held virtually on Tuesday, March 26, 2024 at 8:00 a.m. ET

Visit link:
Praxis Precision Medicines to Host PRAX-628 Program Update

SNK01 autologous NK cell therapy demonstrated a positive effect on cerebral spinal fluid (“CSF”) and plasma Tau proteins in Alzheimer’s patients.

Read the original here:
NKGen Biotech Presents Additional Phase 1 Clinical Trial Data in Alzheimer’s Disease at the Tau2024 Global Conference

QIAstat-Dx Analyzer 2.0 with Software 1.6 release enables mobile access to test results, streamlining diagnostic processes and enhancing patient care // QIAstat-Dx Analyzer 2.0 also offers enhanced epidemiology dashboards and improved remote system management // Growing global presence: Over 4,000 QIAstat-Dx instruments for reliable, fast and cost?effective diagnosis of complex syndromes placed worldwide by the end of 2023 QIAstat-Dx Analyzer 2.0 with Software 1.6 release enables mobile access to test results, streamlining diagnostic processes and enhancing patient care // QIAstat-Dx Analyzer 2.0 also offers enhanced epidemiology dashboards and improved remote system management // Growing global presence: Over 4,000 QIAstat-Dx instruments for reliable, fast and cost?effective diagnosis of complex syndromes placed worldwide by the end of 2023

Read the original post:
QIAGEN introduces QIAstat-Dx Analyzer 2.0 with remote test results access, enhancing collaboration across healthcare system

FORT WORTH, TX, March 25, 2024 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets, announced today its strategic, operational and financial results for the quarter and full year ended December 31, 2023.

Read the original here:
Sanara MedTech Inc. Announces Fourth Quarter and Full Year 2023 Results

WALTHAM, Mass., March 25, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announced financial results for the year ended December 31, 2023, and recent business highlights.

Continued here:
Aerovate Therapeutics Announces Full-Year 2023 Financial Results and Business Highlights

- Sutro highlighted luveltamab tazevibulin (luvelta) in a January 2024 investor webcast, describing the broad opportunity to address unmet needs in multiple FolR?-expressing cancers -

Read more here:
Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones

PRINCETON, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX) (“Agile Therapeutics” or the “Company”), a women's healthcare company, today announced that the Company has received a final delisting notice from Nasdaq.

Read more from the original source:
Agile Therapeutics Announces Delisting from Nasdaq

IRVINE, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced the enrollment of the 12th participant on March 23, 2024, in the Company’s ongoing Phase 2 BESTOW trial assessing tegoprubart head-to-head with tacrolimus for the prevention of rejection in kidney transplantation.

See the rest here:
Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection

NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that U.S. FDA has informed the company that following additional consideration the available clinical data from its Phase 3 study MSB-GVHD001 appears sufficient to support submission of the proposed Biologics License Application (BLA) for remestemcel-L for treatment of pediatric patients with steroid-refractory acute graft versus host disease (SR-aGVHD).

More:
United States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA...

CARBIOS joins Paris Good Fashion to accelerate textile circularity and contribute to more sustainable fashion

Follow this link:
CARBIOS joins Paris Good Fashion to accelerate textile circularity and contribute to more sustainable fashion

Saint-Herblain (France), March 26, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced the initiation of a Phase 1 clinical trial to investigate the

Read more:
Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate

VYVGART® now approved in Japan for both generalized myasthenia gravis and primary immune thrombocytopenia (ITP)

Read more:
argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia